Piper Sandler Initiates Coverage On Gritstone Bio with Overweight Rating, Announces Price Target of $6
Piper Sandler analyst Edward Tenthoff initiates coverage on Gritstone Bio (NASDAQ:GRTS) with a Overweight rating and announces Price Target of $6.
Gritstone Highlights Presentation Of Data From CORAL-BOOST Study
-- New data from CORAL-BOOST study demonstrate broad and durable immune response; high neutralizing antibody and T cell responses at 6 months post-boost vaccination --
-- Interim results from CORAL-CEPI show good
Goldman Sachs Downgrades Gritstone Bio to Sell, Announces $2 Price Target
Goldman Sachs analyst Corinne Jenkins downgrades Gritstone Bio (NASDAQ:GRTS) from Neutral to Sell and announces $2 price target.
Gritstone’s Cancer Drug Shows Strong Tumor-Specific Responses In Various Settings
Gritstone bio Inc (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Earnings Outlook For Gritstone Oncology
Gritstone Oncology (NASDAQ:GRTS) is set to give its latest quarterly earnings report on Thursday, 2022-08-04. Here's what investors need to know before the announcement.
Analysts estimate that Gritstone Oncology will report an earnings per share (EPS) of $-0.40.